

CURRICULUM VITAE AND BIBLIOGRAPHY

Date of Preparation:

April 12, 2018

Personal Data:

Name: Harold Frucht
Birthplace: New York City, NY
Citizenship: USA

Academic Training:

SUNY at Albany, Albany, NY	B.A.	8/1971-8/1975
University of Brussels Medical School, Brussels, Belgium		8/1976-6/1980
SUNY Upstate Medical Center, Syracuse, NY	M.D.	7/1980-6/1982
Licensure: New York, Maryland, Virginia, Florida, Pennsylvania		

Traineeships:

Intern and Resident in Internal Medicine. Upstate Medical Center, Syracuse, NY, 7/1982-6/1985.
Fellow in Gastroenterology. Upstate Medical Center, Syracuse, NY, 7/1985-6/1986.
Medical Staff Fellow in Gastroenterology. Digestive Diseases Branch, NIDDK, National Institutes of Health, Bethesda, MD, 7/1986-6/1989.

Board Certifications:

National Board of Medical Examiners, Part I: June 1979; Part II: September 1981; Part III: March 1983.
American Board of Internal Medicine, September 1986.
ABIM Subspecialty of Gastroenterology, November 1987.

Professional Organizations and Societies:

American College of Physicians
American Gastroenterological Association
American Association for Cancer Research
American Association for the Advancement of Science
American Society for Gastrointestinal Endoscopy
American Society of Clinical Oncology
Southwest Oncology Group (also Member of the Gastrointestinal Committee)

Academic Appointments:

Senior Staff Fellow in Gastroenterology, Digestive Diseases Branch, NIDDK, National Institutes of Health, Bethesda, Maryland, 7/1989-12/1990.
Director of Gastroenterology, Associate Member, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, 1/1991-6/2001.

Associate Professor of Clinical Medicine, Director of Gastrointestinal Oncology, Division of Digestive & Liver Diseases, Department of Medicine, Columbia University College of Physicians & Surgeons, New York, NY, 7/2001-present.

Hospital Appointments:

Intern in Medicine. Upstate Medical Center, Syracuse, NY, 1982-1983.
Resident in Medicine. Upstate Medical Center, Syracuse, NY, 1983-1985.
Fellow in Gastroenterology. Upstate Medical Center, Syracuse, NY, 1985-1986.
Medical Staff Fellow. National Institutes of Health, Bethesda, MD, 1986-1989.
Senior Staff Fellow. National Institutes of Health, Bethesda, MD, 1989-1990.
Director of Gastroenterology. Fox Chase Cancer Center, Philadelphia, PA, 1991-2001.
Director of Endoscopy. Fox Chase Cancer Center, Philadelphia, PA, 1992-1996.
Director of the Gastrointestinal Tumor Risk Assessment Program. Fox Chase Cancer Center, Philadelphia, PA, 1993-1998.
Digestive Diseases Council, New York Presbyterian Hospital, New York, NY, 2002-2006.
Digestive Diseases Cancer Council, New York Presbyterian Hospital, New York, NY, 2007-2009.

Honors:

Distinction, University of Brussels Medical School
Dean's Letter, Upstate Medical Center
Glaxo Fellow Travel Award, 1988 American Gastroenterological Association

Grant and Fellowship Support:

Research Grants, Contracts and Fellowships:

1. Mary L. Smith Charitable Lead Trust. "The Biology of Receptors on Gastrointestinal Tumors" Grant #04269-06-J. Principal Investigator. Total direct costs: \$43,741. 1993-1994.
2. National Cancer Institute. "Regulation of Gastrin Receptors on GI Cancer Cells" Grant #R29 CA70335. Principal Investigator. Total direct costs: \$350,000. 1996-2002.
3. National Cancer Institute. "Colon Cancer Screening for Cancer Patients' Families" Grant #R01 CA75795. Co-Investigator. 1998-2001.
4. National Cancer Institute and NIDDK. "Preneoplastic Lesions of the GI Tract" Unrestricted Conference Grant, AGA Sponsored Symposium. Principal Investigator. Total direct costs: \$4,000. 1999.
5. Columbia Presbyterian Medical Center Clinical Trials Office. "Infrastructure for Columbia Colon Cancer Prevention Program". Principal Investigator. Total direct costs: \$135,714. 2002-2004.
6. National Institute of Aging. "Using Clinical Criteria to Identify Hereditary Colon Cancer Syndromes". Supervising GI Fellow E. Blanco. Total Direct Costs: \$25,000. 2003.
7. Columbia Presbyterian Medical Center Herbert Irving Comprehensive Cancer Center Pilot Award Funding. "Differential Clonal Growth Response of Colon Cancer Cells to Bile Acids". Principal Investigator. Total Direct Costs: \$20,000. 2003-2004.
8. Hirshberg Foundation for Pancreatic Cancer Research Seed Grant Application. "Pancreatic Physiology in the Screening and Early Detection of Human Pancreatic Adenocarcinoma". Principal Investigator. Total Direct Costs: \$30,000. 2006-2007.

9. Irving Institute for Clinical and Translational Research/CTSA Imaging Core Pilot Project. "PET Scans for the Detection of Malignancy in Intraductal Papillary Mucinous Neoplasms (IPMN) of the Pancreas". Mentor. (Principal Investigator - Dr. Caroline Hwang).

Sponsored Clinical Trials:

1. Marion Merrell Dow, Inc. "A Phase III Trial of Oral Sucralfate versus Placebo for the Prophylaxis of Acute and Chronic Bowel Dysfunction after Pelvic Irradiation". Unrestricted Clinical Grant. Principal Investigator. Total direct costs: \$60,000. 1994.
2. Astra-Merck, Inc. "A Randomized Double Blind Placebo Controlled Trial of Oral Omeprazole in the Prophylaxis of Radiation Induced Esophageal Injury in Patients with Esophageal Cancer or Lung Cancer". Unrestricted Clinical Grant. Principal Investigator. Total direct costs: \$30,000. 1995.
3. Repligen Corp. "MRCP with Secretin-Secretion for the Evaluation of Pancreatic Endocrine and Exocrine Function Following Surgical Resection for Pancreatic Adenocarcinoma". Principal Investigator. Material Transfer Agreement for Synthetic Human Secretin RG 1068 FDA IND 76,234. 2006.
4. Repligen Corp. "Secretin- Stimulated MRCP and EUS as Early Screening Modalities for Pancreatic Ductal Abnormalities in Patients at High Risk for Pancreatic Adenocarcinoma: A Pilot Study". Principal Investigator. Material Transfer Agreement for Synthetic Human Secretin RG 1068 FDA IND 76,234. 2006.

Clinical Trials:

1. Columbia Colon Cancer Prevention Program (C3P2) Registry and Tissue Bank for High Risk Individuals. Principal Investigator. WIRB Approved 2/2003.
2. Columbia High-Risk Pancreatic Cancer Registry (C2P3). Principal Investigator. CUMC IRB Approved 7/2004.
3. The Utility of Gastrointestinal Endoscopy Prior to Cardiac Catheterization in Patients with Evidence of Gastrointestinal Bleeding. Principal Investigator. CUMC IRB Approved 4/2007.
4. Secretin-Stimulated MRCP and EUS as Early Screening Modalities for Pancreatic Ductal Abnormalities in Patients at High Risk for Pancreatic Adenocarcinoma: A Pilot Study. Principal Investigator. CUMC IRB Approved 5/2007.
5. MRCP with Secretin-Secretion for the Evaluation of Pancreatic Endocrine and Exocrine Function Following Surgical Resection for Pancreatic Adenocarcinoma. Principal Investigator. CUMC IRB Approved 10/2007.
6. Molecular Genetics and Epidemiology of Pancreatic Cancer in Ashkenazi Jewish Patients. Principal Investigator. CUMC IRB Approved 11/2007.
7. Familial Pancreatic Cancer. Principal Investigator. CUMC IRB Approved 12/2007.
8. Pancreatic Intraepithelial Neoplasia (PanIN) and the Association with Recurrence of Pancreatic Adenocarcinoma. Principal Investigator. CUMC IRB Approved 1/2008.
9. Determination of a Possible Association of Fundic Gland Polyps with the Use of Proton Pump Inhibitor Drugs. CUMC IRB Approved 6/2008.
10. CT Colonography Understanding. Principal Investigator. CUMC IRB Approved 11/2008.
11. Family and Personal History of Malignancy in IPMN. Principal Investigator. CUMC IRB Approved 11/2008.

12. Refining the Molecular Progression from Intraductal to Invasive Pancreatic Cancer: Correlating Genetic Profiles and Clinicopathological Phenotypes in sporadic and Familial Pancreatic Carcinoma. Principal Investigator. CUMC IRB Approved 3/2009.
13. BRCA1 and BRCA2 Genetic Mutations in Mucinous versus Nonmucinous Precursor Lesions of the Pancreas: Validation of a Mouse Model of Pancreatic Carcinogenesis. Principal Investigator. CUMC IRB Approved 5/2009.
14. Detection of Pancreatic Cancer and Precancer by Stool DNA Testing: A Feasibility Study. Principal Investigator. CUMC IRB Approved 7/2009.
15. Use of PET Imaging to Distinguish Malignant from Benign IPMN. Principal Investigator. CUMC IRB Approved 9/2009.
16. Frequency of Methods of Local Invasion of Pancreatic Adenocarcinoma. Principal Investigator. CUMC IRB Approved 9/2009.
17. MRI with secretin enhancement to increase conspicuity of pancreatic cancer. Principal Investigator. CUMC IRB Approved 4/2010.
18. Health History Questionnaire vs. Genetic Counselor Family History. Principal Investigator. CUMC IRB Approved 2/2011.
19. Pancreatic Cancer in Minorities. Principal Investigator. CUMC IRB Approved 6/2011.

Departmental and University Committees:

1. Chairman, Endoscopy Committee. Fox Chase Cancer Center, Philadelphia, PA, 1993-1996.
2. Gastrointestinal Fellow Credential Committee. Presbyterian Medical Center, Philadelphia, PA, 1993-1996.
3. Gastrointestinal Fellow Credential Committee. Thomas Jefferson University Medical Center, Philadelphia, PA, 1996-1998.
4. Director, Gastrointestinal Fellowship Program. Fox Chase Cancer Center, Philadelphia, PA, 1993-1998.
5. Value Analysis Committee. Fox Chase Cancer Center, Philadelphia, PA, 1993-2001.
6. Division of Digestive & Liver Diseases Postgraduate Training and Education Committee. Columbia University College of Physicians & Surgeons, New York, NY, 2001-2009.
7. Director of Gastrointestinal Oncology. Division of Digestive & Liver Diseases, New York Presbyterian Hospital – Columbia, New York, NY, 2001-present.
8. Director of the Columbia Colon Cancer Prevention Program (C3P2). Division of Digestive & Liver Diseases, New York Presbyterian Hospital – Columbia, New York, NY, 2002-2009.
9. Department of Medicine Resident Selection Committee. Columbia University College of Physicians & Surgeons, New York, NY, 2003-2009.
10. Executive Board, Pancreas Center of Columbia University Medical Center. Columbia University College of Physicians & Surgeons, New York, NY, 2006-2012.
11. Director, Pancreas Cancer Prevention and Genetics Program, Pancreas Center of Columbia University Medical Center. Columbia University College of Physicians & Surgeons, New York, NY, 2006-2012.

Teaching Experience and Responsibilities:

Courses:

Invited lectures at outside institutions are not listed

1. Philadelphia Gastrointestinal Training Group, Program Committee, Philadelphia, PA, 1993-1994.
2. Cancer Genetics, Resident Lecture Series, Fox Chase Cancer Center, Philadelphia, PA, 1996-2001.
3. Premalignant Lesions of the Gastrointestinal Tract, Director, Ft. Lauderdale, FL, 2/12-14/1999.
4. Faculty Lecturer, Update in Gastroenterology, Hepatology & Nutrition Annual Postgraduate Medicine Course, Columbia University & Cornell University, New York, 2001-2003

5. Faculty Lecturer, Gastroenterology Fellow's Didactic Lecture Series, Division of Digestive & Liver Diseases, Columbia University, New York, NY, 2001-
6. Faculty Lecturer, Internal Medicine Housestaff Lecture Series, Department of Medicine, Columbia University, New York, 2001-
7. Faculty Lecturer, Division of Digestive & Liver Diseases Grand Rounds, Columbia University, New York, NY, 2001
8. Director, Multidisciplinary GI Cancer Conference, Columbia University, New York, NY, 2001-2005
9. International Meeting, GI Malignancies Can Be Prevented And Treated, Scientific Advisory Board, Dead Sea, Israel, 1/15-20/2002
10. Faculty Lecturer, Science Basic to the Practice of Medicine and Dentistry, Columbia University, New York, NY, 2002
11. Faculty Lecturer, Department of Medicine Team Rounds, Columbia University, New York, NY, 6/2002
12. Harkness Report, Department of Medicine, Columbia University, New York, 2003-
13. Faculty Lecturer, Allen Pavilion Department of Medicine Grand Rounds, Columbia University, New York, NY, 4/2003

Clinical Teaching:

1. Resident Supervisor for Medical Students, Medicine Wards, Upstate Medical Center, Syracuse, NY, 1983-1985.
2. Fellow Supervisor for Residents, Gastrointestinal Service, Upstate Medical Center, Syracuse, NY, 1985-1986.
3. Attending, Oncology Service, Fox Chase Cancer Center, Philadelphia, PA, 1991.
4. Supervision of Oncology Fellows, Gastrointestinal Oncology Clinic, Fox Chase Cancer Center, Philadelphia, PA, 1991.
5. Attending, Gastroenterology Consult Service, Fox Chase Cancer Center, Philadelphia, PA, 1991-2001
6. Supervision of Gastroenterology Fellows, Gastrointestinal Clinic, Fox Chase Cancer Center, Philadelphia, PA, 1993-1998.
7. Preceptor, Physical Diagnosis Course, Temple University Medical Center, Philadelphia, PA, 1995 and 2000.
8. Attending, Gastroenterology Consult Service, New York Presbyterian Hospital – Columbia, New York, NY, 2001-2012.
9. Supervision of Gastroenterology Fellows, Gastrointestinal Clinic, New York Presbyterian Hospital – Columbia, New York, NY, 2001-2012.
10. Attending, Internal Medicine Service, New York Presbyterian Hospital – Columbia, New York, NY, 2002-2012.
11. Preceptor, Medical Student Electives, Columbia University, New York, NY, 2002 – 2012.
12. Preceptor, Third Year Clinical Clerkship in Medicine, Columbia Univ, New York, NY, 2004 – 2012.
13. Supervision of Gastroenterology Fellows, High-Risk GI Cancer/Clinical GI Genetics Program, New York Presbyterian Hospital – Columbia, New York, NY, 2006-2009.

Other Professional Activities:

Editorial:

Ad Hoc Reviewer. *American Journal of Physiology, Annals of Internal Medicine, Cancer, Cancer Research, Clinical Cancer Research, Clinical Gastroenterology and Hepatology, Digestive Diseases & Sciences, Gastroenterology, Journal of the National Cancer Institute, Cancer Epidemiology Biomarkers & Prevention.*

Consultative:

Ad Hoc Grant Reviewer. National Institutes of Health, Veterans Administration.

Publications:

Original, Peer Reviewed Articles:

1. Maton PN, **FRUCHT H**, Vinayek R, Wank SA, Gardner JD, Jensen RT. Medical management of patients with Zollinger-Ellison Syndrome who have had previous gastric surgery: A prospective study. *Gastroenterology* 1988;94:294-299.
2. vonSchrenk T, Howard JM, Doppman JL, Norton JA, Maton PN, Smith F, Vinayek R, **FRUCHT H**, Wank SA, Gardner JD, Jensen RT. Prospective study of chemotherapy in patients with metastatic gastrinoma. *Gastroenterology* 1988;94:1326-1334.
3. Trepel JB, Moyer JD, Cuttitta F, **FRUCHT H**, Coy DH, Natale RB, Mulshine JL, Jensen RT, Sausville EA. A novel bombesin receptor antagonist inhibits autocrine signals in a small cell lung carcinoma cell line. *Biochem. Biophys. Res. Comm.* 1988;56:1383-1389.
4. **FRUCHT H**, Doppman JL, Norton JA, Miller DL, Dwyer AJ, Frank JA, Vinayek R, Maton PN, Jensen RT. Gastrinomas: Comparison of MR Imaging with CT, angiography and ultrasound. *Radiology* 1989;171:713-717.
5. Maton PN, Vinayek R, **FRUCHT H**, McArthur KA, Miller LS, Saeed ZA, Gardner JD, Jensen RT. Long term efficacy and safety of omeprazole in patients with Zollinger-Ellison Syndrome: A prospective study. *Gastroenterology* 1989;97:827-836.
6. **FRUCHT H**, Howard JM, Slaff JI, Wank SA, McCarthy DM, Maton PN, Vinayek R, Gardner JD, Jensen RT. Secretin and calcium provocative tests in the Zollinger-Ellison Syndrome. A prospective study. *Ann. Intern. Med.* 1989;111:713-722.
7. **FRUCHT H**, Howard JM, Stark HA, McCarthy DM, Maton PN, Gardner JD, Jensen RT. Prospective study of the standard meal provocative test in Zollinger-Ellison Syndrome. *Am. J. Med.* 1989;87:528-536.
8. Miller LS, Vinayek R, **FRUCHT H**, Gardner JD, Jensen RT, Maton PN. Reflux esophagitis in patients with Zollinger-Ellison Syndrome: A prospective study. *Gastroenterology* 1990;98:341-346.
9. Wang L-H, Coy DH, Taylor JE, Jiang N-Y, Kim SH, Moreau J-P, Huang SC, Mantey SA, **FRUCHT H**, Jensen RT. Des-Met alkylamide bombesin receptor antagonist with potent antisecretory activity in pancreatic acini and antimitotic activity in Swiss 3T3 cells. *Biochemistry* 1990;29:6121-6122.
10. Park J-G, **FRUCHT H**, LaRocca RV, Bliss D, Kurita Y, Chen T-R, Henslee JG, Trepel J, Jensen RT, Johnson BE, Bang Y-J, Kim J-P, Gazdar AF. Characteristics of cell lines established from human gastric carcinoma. *Cancer Res.* 1990;50:2773-2780.
11. Vinayek R, **FRUCHT H**, London JF, Miller LS, Stark HA, Norton JA, Jensen RT, Gardner JD, Maton PN. The use of intravenous omeprazole in patients with Zollinger-Ellison Syndrome (ZES) undergoing surgery. *Gastroenterology* 1990;99:10-16.
12. Wang LH, Coy DH, Taylor JE, Jiang NY, Moreau JP, Huang SC, **FRUCHT H**, Haffar BM, Jensen RT. Des-met carboxyl-terminally modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists or agonists. *J. Biol. Chem.* 1990;263:15695-15703.
13. **FRUCHT H**, Notron JA, London JF, Vinayek R, Doppman JL, Gardner JD, Jensen RT, Maton PN. Detection of duodenal gastrinomas by operative endoscopic transillumination. A prospective study. *Gastroenterology* 1990;99:1622-1627.
14. Viallet J, Sharoni Y, **FRUCHT H**, Jensen RT, Minna JD, Sausville EA. Cholera toxin inhibits mitogen response and the growth of human small cell lung cancer *in vitro*. *J. Clin. Invest.* 1990;86:1904-1912.
15. London JF, Shawker TH, Doppman JL, Miller DL, **FRUCHT H**, Vinayek R, Stark HA, Miller LS, Norton JA, Jensen RT, Gardner JD, Maton PN. Prospective assessment of abdominal ultrasound in patients with Zollinger-Ellison Syndrome. *Radiology* 1991;178:763-767.

16. Vinayek R, Amantea M, Maton PN, **FRUCHT H**, Gardner JD, Jensen RT. Pharmacokinetics of oral and intravenous omeprazole in patients with Zollinger-Ellison Syndrome. *Gastroenterology* 1991;101:138-147.
17. Coy DH, Jiang NY, Kim SH, Moreau JP, Lin JT, **FRUCHT H**, Qian JM, Wang LW, Jensen RT. Covalently-cyclized agonist and antagonist analogues of bombesin and related peptides. *J. Biol. Chem.* 1991;266:16441-16447.
18. **FRUCHT H**, Gazdar AF, Park JA, Oie H, Jensen RT. Characterization of functional receptors for gastrointestinal hormones on human colon cancer cells. *Cancer Res.* 1992;52:1114-11122.
19. Wang LH, Mantey SA, Lin JT, **FRUCHT H**, Jensen RT. Ligand binding internalization, degradation and regulation by guanine nucleotides of bombesin receptor subtypes: A comparative study. *Biochim. Biophys. Acta* 1993;1175:232-242.
20. Mantey SA, **FRUCHT H**, Coy DH, Jensen RT. Characterization of bombesin receptors with a novel potent radiolabeled bombesin antagonist that distinguishes receptor subtypes. *Mol. Pharmacol.* 1993;43:762-774.
21. O'Dwyer PJ, Lacreata FP, Haas NB, Halbherr T, **FRUCHT H**, Goosenberg E, Yao K. Clinical pharmacokinetic and biological studies of topotecan. *Cancer Chemother. Pharmacol.* 1994;34(suppl):S46-S52.
22. Szarka CE, Pfeiffer GR, Hum ST, Everley LC, Balschem AM, Moore DF, Litwin S, Goosenberg EB, **FRUCHT H**, Engstrom PF, Clapper ML. Glutathione S-transferase activity and glutathione S-transferase μ expression in subjects with risk of colorectal cancer. *Cancer Res.* 1995;55:2789-2793.
23. O'Dwyer PJ, Szarka CE, Yao KS, Halbherr TC, Pfeiffer GR, Green F, Hum ST, Gallo JM, Brennan J, **FRUCHT H**, Goosenberg EB, Hamilton TC, Litwin S, Balschem AM, Engstrom PF, Clapper ML. Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. *J. Clin. Invest.* 1996;98:12110-12117.
24. Clapper ML, Szarka CE, Pfeiffer GR, Graham TA, Balschem AM, Litwin S, Goosenberg EB, **FRUCHT H**, Engstrom PF. Preclinical and clinical evaluation of broccoli supplements as inducers for detoxification enzyme activity. *Clin. Cancer Res.* 1997;3:25-30.
25. **FRUCHT H**, Jensen RT, Dexter D, Yang W-L, Xiao Y. Human colon cancer cell proliferation mediated by the M₃ muscarinic cholinergic receptor. *Clin. Cancer Res.* 1999;5:2532-2539.
26. Yang W-L, **FRUCHT H**. Cholinergic receptor up-regulates cox-2 expression and prostaglandin E₂ production in colon cancer cells. *Carcinogenesis* 2000;21:1789-1793.
27. Szarka C, Yao K-S, Pfeiffer GR, Balschem AM, Litwin S, **FRUCHT H**, Goosenberg EB, Engstrom PF, Clapper ML, O'Dwyer PJ. Chronic dosing of oltipraz in people at increased risk for colorectal cancer. *Cancer Detect Prev.* 2001;25:352-361.
28. Yang W-L, **FRUCHT H**. Activation of the PPAR pathway induces apoptosis and cox-2 inhibition in HT-29 human colon cancer cells. *Carcinogenesis* 2001;22:1379-1383.
29. Cheng K, Chen Y, Zimniak P, Raufman J-P, Xiao Y, **FRUCHT H**. Functional interaction of lithocholic acid conjugates with M₃ muscarinic receptors on a human colon cancer cell line. *Biochim. Biophys. Acta.* 2002;1588:48-55.
30. Gatto NM, **FRUCHT H**, Sundararajan V, Jacobson JS, Grann VR, Neugut AI. Risk of perforation following colonoscopy and sigmoidoscopy: A population based study. *J Natl Cancer Inst.* 2003;95:230-236.
31. Larghi A, Leffler D, **FRUCHT H**, Rubin M, Semrad CE, Lefkowitz JH, Worman HJ. Hepatitis B Virus Reactivation After Kidney Transplantation and New Onset Lymphoma. *J Clin Gastroenterol.* 2003;36:276-280.
32. Goldberg M, Farma J, Lampert C, Colarusso P, Coia L, **FRUCHT H**, Goosenberg E, Beard M, Weiner LM. Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I report. *J Thorac Cardiovasc Surg.* 2003;126:1168-73.
33. Schönleben F, Qiu W, Bruckman KC, Ciau NT, Li X, Lauerman MH, **FRUCHT H**, Chabot JA, Allendorf JD, Remotti HE, Su GH. BRAF and KRAS Mutations in Intraductal Papillary Mucinous Neoplasm/Carcinoma (IPMN/IPMC) of the Pancreas. *Cancer Letters.* 2007; 249:2 242-248.

34. Vinarsky V, Fine R, Assaad A, Qian Y, Chabot J, Su G, **FRUCHT H**. Head and Neck Squamous Cell Carcinoma in FAMMM Syndrome. *Head and Neck*. 2009; 31:11 524-7.
35. Shankaran V, Ha Luu T, Nonzee N, Richey E, McKoy J, Zivin J, Ashford A, Lantigua R, **FRUCHT H**, Scoppettone M, Bennett C, Sheinfeld Gorin S. Costs and Cost-Effectiveness of a Health Care Provider-Directed Intervention to Promote Colorectal Cancer (CRC) Screening. *J Clinical Oncology*. 2009; 27:32 5370-5.
36. Verna EC, Hwang C, Stevens PD, Rotterdam H, Stavropoulos SN, Sy CD, Prince MA, Chung WK, Fine RL, Chabot JA, **FRUCHT H**. Pancreatic Cancer Screening in a Prospective Cohort of High Risk Patients: A Comprehensive Strategy of Imaging and Genetics. *Clin Cancer Research*. 2010;16:20 5028-37.
37. Chang MS, Shah JP, Amin, S, Gonzalez, S, Prowda, JC, Cheng JM, Verna EC, Rockey DC, **FRUCHT H**. Physician Knowledge and Appropriate Utilization of Computed Tomographic Colonography in Colorectal Cancer Screening. *Abdom Imaging*. 2011; 36:5 524-31.
38. Amin S, McBride R, Kline J, Mitchel EB, Lucas AL, Neugut AI, **FRUCHT H**. Incidence of Subsequent Pancreatic Adenocarcinoma in Patients with a History of Non-Pancreatic Primary Cancers. *Cancer*. 2012; 118:5 1244-1251.
39. Amin S, Lucas AL, **FRUCHT H**. Evidence for Treatment and Survival Disparities by Age in Pancreatic Adenocarcinoma: A Population Based Analysis. *Pancreas*. 2013; 42:249-53.
40. Asfaha S, Dubeykovskiy AN, Tomita H, Yang X, Stokes S, Shibata W, Friedman RA, Ariyama H, Dubeykovskaya ZA, Muthupalani S, Ericksen R, **FRUCHT H**, Fox JG, Wang TC. Mice that Express Human Interleukin-8 Have Increased Mobilization of Immature Myeloid Cells which Exacerbates Inflammation and Accelerates Colon Carcinogenesis. *Gastroenterology*. 2013; 144:155-166.
41. Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijdt I, Levy MJ, Chak A, Fockens P, Goggins M, Bruno M; International Cancer of the Pancreas Screening (CAPS) Consortium (**FRUCHT H**). International Cancer of the Pancreas Screening (CAPS) Consortium Summit on the Management of Patients with Increased Risk for Familial Pancreatic Cancer. *Gut*. 2013; 62:339-47.
42. Lucas AL, Shakya R, Lipsyc MD, Mitchel EB, Kumar S, Hwang C, Deng L, Devoe C, Chabot JA, Szabolcs M, Ludwig T, Chung WK, **FRUCHT H**. High Prevalence of *BRCA1* and *BRCA2* Germline Mutations With Loss of Heterozygosity In a Series of Resected Pancreatic Adenocarcinoma and Other Neoplastic Lesions. *Clin Cancer Research*. 2013; 19:3396-3403.
43. Hassid BG, Lucas AL, Salomao M, Weng C, Liu F, Khanna LG, Kumar S, Hwang C, Chabot JA, **FRUCHT H**. Absence of Pancreatic Intraepithelial Neoplasia (PanIN) Predicts Poor Survival Following Resection of Pancreatic Cancer. *Pancreas*. 2014; 43:1073-1077.
44. Lucas AL, Frado L, Hwang C, Kumar S, Khanna LG, Levinson E, Chabot JA, Chung WK, **FRUCHT H**. *BRCA1* and *BRCA2* Germline Mutations are Frequently Demonstrated in Both High Risk Pancreatic Cancer Screening and Pancreatic Cancer Cohorts. *Cancer*. 2014; 120:1960-1967.
45. Lucas AL, Tarlecki A, Van Beck K, Lipton C, RoyChoudhury A, Levinson E, Kumar S, Chung WK, **FRUCHT H**, Genkinger JM. Self-Reported Questionnaire Detects Family History of Cancer in a Pancreatic Cancer Screening Program. *J Genet Couns*. 2017; 806-813.
46. McWilliams RR, Wieben ED, Chaffee MS, Antwi SO, Raskin L, Olopade OI, Li D, Highsmith WE, Colon-Otero G, Khanna LG, Permuth JB, Olson JE, **FRUCHT H**, Genkinger J, Zheng W, Blot WJ, Wu L, Almada LL, Fernandez-Zapico ME, Sicotte H, Pedersen KS, Peterson GM. CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations. *Cancer Epidemiol Biomarkers Prev*. 2018. In Press.

Reviews:

1. London JF, **FRUCHT H**, Doppman JD, Maton PN, Gardner JD, Jensen RT. Zollinger-Ellison Syndrome in the intensive care setting. *J. Intensive Care Med*. 1989;4:272-283.

2. Vinayek R, **FRUCHT H**, Chiang HCV, Maton PN, Gardner JD, Jensen RT. Zollinger-Ellison Syndrome: Recent advances in the management of the gastrinoma. *Gastroenterological Clinics of North America* 1990;19:197-217.
3. **FRUCHT H**, Maton PN, Jensen RT. The use of omeprazole in patients with Zollinger-Ellison Syndrome. *Dig. Dis. Sci.* 1991;36:394-404.
4. Ahmad NR, Goosenberg EB, **FRUCHT H**, Coia LR. Palliative treatment of esophageal cancer. *Semin. in Radiat. Oncol.* 1994;4:202-214.
5. Calvert P, **FRUCHT H**. The genetics of colorectal cancer. *Ann. Intern. Med.* 2002; 137:603-612.
6. **FRUCHT H**, Stevens PD, Fogelman DR, Verna EC, Chen J, Chabot JA, Fine RL. Advances in the Genetic Screening, Work-up, and Treatment of Pancreatic Cancer. *Curr Treat Options Gastroenterol.* 2004; 7:343-354.
7. Lucas AL, Hwang C, **FRUCHT H**. Strengthening the Case for Stool DNA Tests as First-Line Colorectal Cancer Screening: Are We There Yet? *Clin Gastroenterol Hepatol.* 2012; 10:214-215.
8. Becker A, Hernandez Y, **FRUCHT H**, Lucas AL. Pancreatic Ductal Adenocarcinoma: Risk Factors, Screening, & Early Detection. *World Journal of Gastroenterology.* 2014; 20:11182-11198.

Books and Book Chapters:

1. Eisenberg BE, Szarka CE, **FRUCHT H**, Lanciano RM, Hageboutros A and Weiner LM. Gastric Cancer. In: James C. Harvey and Edward Beattie (eds): "Cancer Surgery" New York: WB Saunders Co., 1995.
2. Meropol NJ, Lewis NL, **FRUCHT H**. Colorectal Cancer: A Practical Overview. Neal J. Meropol, Nancy L. Lewis, and Harold Frucht (eds). Philadelphia: Elsevier Science, 2002
3. **FRUCHT H**. The Genetics of Colorectal Cancer. In: UpToDate, Rose, BD (ed): UpToDate, Wellesley, MA, 2003 - .
4. Lucas AL, Chang MM, Lipsyc MD, **FRUCHT H**. The Prevention and Genetics of Pancreatic Cancer: A Programmatic Approach. In: Gloria H. Su (ed): Pancreatic Cancer: Methods and Protocols, Methods in Molecular Biology. 2013; 980:205-214.

Presentations at Scientific Meetings and Abstracts:

1. **FRUCHT H**, Doppman JL, Maton PN, Norton JA, Wank SA, Gardner JD, Jensen RT. Prospective study of the ability of magnetic resonance imaging (MRI) to localize gastrinomas. Submitted to the American Gastroenterological Association Meeting, May, 1987. Published *Gastroenterology* 1987;92(5):1397.
2. Maton PN, **FRUCHT H**, Vinayek R, Wank SA, Norton JA, Gardner JD, Jensen RT. Criteria for medical therapy in patients with Zollinger-Ellison Syndrome (ZES) who have had previous gastric surgery. Presented at the American Gastroenterological Association Meeting, May, 1987. Published *Gastroenterology* 1987;92(55):1520.
3. **FRUCHT H**, Norton JA, Maton PN, Miller LS, Stark HA, Saeed ZA, Gardner JD, Jensen RT. Intraoperative endoscopy (IOE) detects a high frequency of duodenal gastrinoma in patients with Zollinger-Ellison Syndrome. Presented at the American Gastroenterology Association Meeting, May, 1988. Published *Gastroenterology* 1988;94(5):137.
4. Maton PN, Lack E, McArthur KA, Collen MJ, **FRUCHT H**, Miller LS, Saeed ZA, Gardner JD, Jensen RT. Effects of long term omeprazole on gastric acid secretion and mucosal histology in patients with Zollinger-Ellison Syndrome (ZES). Presented at the American Gastroenterological Association Meeting, May, 1988. Published *Gastroenterology* 1988;94(5):288.

5. Miller LS, **FRUCHT H**, Saeed ZA, Gardner JD, Jensen RT. Esophageal involvement in Zollinger-Ellison Syndrome (ZES). Presented at the American Gastroenterological Association Meeting, May, 1988. Published *Gastroenterology* 1988;94(5):304.
6. Saeed ZA, Frank W, **FRUCHT H**, Wank SA, Vinayek R, Maton PN, Norton JA, Gardner JD, Jensen RT. Management of gastric hypersecretion with intravenous antisecretory medication in patients with Zollinger-Ellison Syndrome (ZES). Presented at the American Gastroenterological Association Meeting, May, 1988. Published *Gastroenterology* 1988;94(5):393.
7. Maton PN, Lack E, Vinayek R, Collen MJ, **FRUCHT H**, Miller LS, Gardner JD, Jensen RT. Prospective assessment of the safety and efficacy of long-term omeprazole therapy in patients with Zollinger-Ellison Syndrome. Presented at the International Symposium on Omeprazole, November, 1988. Published *Scandinavian Journal of Gastroenterology* 1989;24(Suppl 166):181.
8. **FRUCHT H**, Oie HK, Park J-G, Gazzdar AF, Gardner JD, Jensen RT. Presence of peptide receptors on newly established human colon cancer cell lines. Submitted to the American Gastroenterological Association Meeting, May, 1989. Published *Gastroenterology* 1989;96(5):A-161.
9. London JF, Vinayek R, **FRUCHT H**, Stark HA, Miller LS, Norton JA, Shawker TD, Jensen RT, Gardner JD, Maton PN. Prospective assessment of the value of trans-abdominal ultrasonography (US) in localizing gastrinomas. Presented at the American Gastroenterological Association Meeting, May, 1989. Published *Gastroenterology* 1989;96(5):A-307.
10. Vinayek R, London JF, **FRUCHT H**, Stark HA, Miller L, Jensen RT, Gardner JD, Maton PN. The use of intravenous omeprazole in patients with Zollinger-Ellison Syndrome (ZES) undergoing surgery. Presented at the American Gastroenterological Association Meeting, May, 1989. Published *Gastroenterology* 1989;96(5):A-531.
11. **FRUCHT H**, Park JG, Oie HK, Gazzdar AF, Gardner JD, Jensen RT. Study of newly established human gastric cancer cell lines for peptide receptors. Presented at the American Association for Cancer Research Meeting, May, 1989. Published *Proceedings of the American Association for Cancer Research* 1989;30:67.
12. Mantey S, Coy DH, Jiang N-Y, Wang L-H, **FRUCHT H**, Jensen RT. Characterization of bombesin receptors using a potent radiolabeled antagonist. Presented at the American Gastroenterological Association Meeting, May, 1990. Published *Gastroenterology* 1990;98(5):A-508.
13. **FRUCHT H**, Norton JA, Gardner JD, Jensen RT, Maton PN. Duodenal transillumination detects a high frequency of gastrinomas. Presented at the American Association for Cancer Research Meeting, May, 1990. Published *Proceedings of the American Association for Cancer Research* 1990;31:165.
14. Mantey S, Coy DH, **FRUCHT H**, Gardner JD, Jensen RT. Interaction of bombesin (Bn) receptor agonists but not antagonists is regulated by guanine nucleotides. Presented at the American Gastroenterological Association Meeting, May, 1991. Published *Gastroenterology* 1991;100(5):A-286.
15. **FRUCHT H**, Gazzdar A, Oie H, Jensen RT. Human colon cancer cell lines possess functional M3 type muscarinic cholinergic receptors. Presented at the American Gastroenterological Association Meeting, May, 1991. Published *Gastroenterology* 1991;100(5):A-364.
16. Mantey S, **FRUCHT H**, Coy DH, Jiang N-Y, Gardner JD, Jensen RT. A new potent radiolabeled bombesin (Bn) antagonist distinguishes receptor subtypes. Presented at the American Gastroenterological Association Meeting, May, 1991. Published *Gastroenterology* 1991;100(5):A-654.
17. Wang L-H, Wada E, Battay JF, **FRUCHT H**, Coy DH, Gardner JD, Jensen RT. The rat glial tumor cell line C-6 possesses functional high affinity neuromedin B-(NMB) preferring bombesin receptors. Presented at the American Gastroenterological Association Meeting, May, 1991. Published *Gastroenterology* 1991;100(5):A-674.
18. **FRUCHT H**, Gazzdar A, Jensen RT. Human colon cancer cell line NCI-H716 expresses functional bombesin receptors. Presented at the American Association for Cancer

- Research Meeting, May, 1991. Published *Proceedings of the American Association for Cancer Research* 1991;32:47.
19. Bang Y-J, Fang W-G, **FRUCHT H**, Pirnia F, Jensen RT, Myers CE, Trepel JB. Adenine nucleotides inhibit the growth of androgen-independent prostate carcinoma cells. Presented at the American Society of Clinical Oncology Meeting, May, 1993. Published *Proceedings of the American Society of Clinical Oncology* 1991,10:79.
 20. Szarka CE, Clapper ML, **FRUCHT H** and Engstrom PF. Decreased glutathione S-transferase (GST) activity in subjects with a history of colon cancer. Presented at the American Society of Clinical Oncology Meeting, May, 1993. Published *Proceedings of the American Society of Clinical Oncology* 1993;12:168.
 21. Szarka CE, Pfeiffer GR, **FRUCHT H**, Goosenberg EB, Litwin S, Engstrom PF and Clapper ML. Glutathione S-transferase activity of blood lymphocytes as a marker of human colon glutathione S-transferase activity. Presented at the American Association for Cancer Research Meeting, May, 1994. Published *Proceedings of the American Association for Cancer Research* 1994;35:633.
 22. O'Dwyer PJ, Szarka CE, Gallo JM, Yao K-S, Hum ST, Greene F, Halbherr TC, Brennan J, Pfeiffer GR, **FRUCHT H**, Goosenberg EB, Engstrom PF and Clapper ML. Phase I/Pharmacodynamic trial of the chemopreventive agent oltipraz. Presented at the American Society of Clinical Oncology Meeting, May, 1994. Published *Proceedings of the American Society of Clinical Oncology* 1994;13:144.
 23. Szarka CE, Gallo JM, Yao KS, Hum ST, Greene F, Halbherr TC, Brennan J, Pfeiffer GR, **FRUCHT H**, Goosenberg EB, Engstrom PF, Clapper ML, O'Dwyer PJ. Induction of gene transcription in humans by low doses of the dithiolethione oltipraz. Presented at the American Society of Clinical Oncology Meeting, May, 1995. Published *Proceedings of the American Society of Clinical Oncology* 1995;14:166.
 24. Szarka CE, Raskay BJ, Pfeiffer GR, Everley LC, Halbherr TC, Yao K-S, Balshem AM, Litwin S, **FRUCHT H**, Goosenberg EB, Engstrom PF, Clapper ML, O'Dwyer PJ. Oltipraz in individuals at high risk for colorectal cancer. Submitted to the American Society of Clinical Oncology, May, 1996. Published *Proceedings of the American Society of Clinical Oncology* 1996;15:173.
 25. Weiner LM, Colarusso P, Coia LR, Goldberg M, Dresler C, **FRUCHT H**, Goosenberg E, Green F, Schmidt K. Combined modality therapy for esophageal cancer: Phase I trial of escalating doses of taxol in combination with cisplatin, fluorouracil, and 60 Gy radiation prior to esophagectomy. Submitted to the American Society of Clinical Oncology, May, 1997. Published *Proceedings of the American Society of Clinical Oncology* 1997;16:309.
 26. **FRUCHT H**, Jensen RT, Dexter D, Xiao Y. Functional expression of m₃ muscarinic cholinergic receptors on human colon cancer cell lines. Presented at the American Gastroenterological Association Meeting, May 1998. Published *Gastroenterology* 1998;114(4):A-598.
 27. **FRUCHT H**, Wank SA, Tamasova N, Xiao Y. Uncoupling of the expression and function of CCK-B/gastric receptors on human colon cancer cell lines. Presented at the American Gastroenterological Association Meeting, May 1998. Published *Gastroenterology* 1998;114(4):A-598.
 28. Yang W-L, Xiao Y, **FRUCHT H**. Cox-2 expression in colon cancer cells is regulated by the M₃ muscarinic cholinergic receptor – A possible mechanism for carbachol-elicited protection from NS-398-induced apoptosis. Presented at the American Gastroenterological Association Meeting, May, 1999. Published *Gastroenterology* 1999;116(4):A-533.
 29. Lampert C, Colarusso P, Goldberg M, Coia L, Dresler C, **FRUCHT H**, Goosenberg E, Beard M, Weiner LM. Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil and radiation in resectable esophageal carcinoma. Presented at the American Society of Clinical Oncology Meeting, May, 1999. Published *Proceedings of the American Society of Clinical Oncology* 1999;18:251a.
 30. **FRUCHT H**, Movsas B, Hanlon AL, Goosenberg E, Hoffman J, Cooper H, Lanciano R, Lee WR, Schultheiss T, Hanks GE. Oral sucralfate reduces the late GI effects of conformal RT for prostate cancer: A double-blinded placebo-controlled randomized trial. Presented

- at the American Society for Therapeutic Radiology and Oncology Meeting, November, 1999. Published *International Journal of Radiation Oncology, Biology, Physics* 1999;45 (3 supp):71.
31. Tiwari S, Movsas B, Hanks G, Bruner D, Pinover W, Horwitz E, Goosenberg E, Hanlon A, **FRUCHT H**. Quality of life (FACT-C) scores remain at baseline following conformal radiotherapy for prostate cancer: A prospective study. Presented at the American Society for Therapeutic Radiology and Oncology Meeting, November, 1999. Published *International Journal of Radiation Oncology, Biology, Physics* 1999;45 (3 supp):83.
 32. Yang W-L, **FRUCHT H**. Activation of PPAR γ induces apoptosis and inhibits cox-2 in human colon cancer cells. Presented at the American Gastroenterological Meeting, May, 2000. Published *Gastroenterology* 2000;118(4):A682.
 33. Raufman J-P, Cheng K, Zimniak P, Xiao Y, **FRUCHT H**. Interaction of taurine conjugates of lithocholic acid with M $_3$ muscarinic receptors on a colon cancer cell line. Presented at the American Gastroenterological Meeting, May, 2000. Published *Gastroenterology* 2000;118(4):A558.
 34. Goldberg M, Lampert C, Colarusso P, Coia L, Farma J, **FRUCHT H**, Goosenberg E, Beard M, Weiner LM. Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil and radiation in respectable esophageal carcinoma: a phase 1 report. Presented at the American Society of Clinical Oncology Meeting, May, 2002. Published *Proceedings of the American Society of Clinical Oncology* 2002;21:154a.
 35. Dimairo CJ, Hwang C, Chabot JA, Stavropoulos SN, **FRUCHT H**, Stevens PD. Characteristics of duodenal neoplasms that impact the decision of endoscopic or surgical management: experience at a large tertiary referral center. Presented at the American Society of Gastrointestinal Endoscopy Meeting, May, 2007. Published *Gastrointestinal Endoscopy* 2007;65(5):AB171.
 36. Sharaf R, McBride R, Kline J, Neugut AI, **FRUCHT H**. Incidence of pancreatic adenocarcinoma is increased in young individuals with metachronous syndromic cancers. Presented at the American Gastroenterological Meeting, May, 2007. Published *Gastroenterology* 2007;132(4):A302.
 37. Vinarsky V, Fine RL, Assaad A, Qian Y, Chabot JA, Su GH, **FRUCHT H**. Head and neck squamous cell cancer as part of the germline p16/INK4a mutation-induced FAMMM syndrome. Presented at the American Society of Clinical Oncology Meeting, May, 2007. Published *Proceedings of the American Society of Clinical Oncology* 2007;25:311s.
 38. Hwang C, Rotterdam H, Bill AZ, Verna E, Lucas AL, Goetz N, Chabot JA, **FRUCHT H**. High-Grade Pancreatic Neoplasia (PanIN) Is Associated with Local Recurrence of Pancreatic Adenocarcinoma After "Curative" Surgical Resection. Presented at the American Gastroenterological Meeting, May, 2008. Published *Gastroenterology* 2008;134(4):A93.
 39. Lucas AL, Bill AZ, Hwang C, Verna E, Goetz N, Chabot JA, **FRUCHT H**. Family History of Pancreas, Breast, Colon, Bladder, and Prostate Cancer in Patients with Pancreas Cancer Supports a Syndromic Predisposition. Presented at the American Gastroenterological Meeting, May, 2008. Published *Gastroenterology* 2008;134(4):A607.
 40. Verna EC, Sy C, Stevens PD, Stavropoulos S, Hwang C, Chabot JA, **FRUCHT H**. Pancreatic Cancer Screening in a Prospective Cohort of High Risk Patients: An Effective and Comprehensive Strategy of Genetics and Imaging. Presented at the American Gastroenterological Meeting, May, 2009. Published *Gastroenterology* 2009.
 41. Khanna LG, Hwang C, Verna E, Lucas AL, Kumar S, Pursell L, Rosario V, Chabot JA, **FRUCHT H**. Significance of Family History of Pancreatic and Associated Syndromic Cancers in Patients with Intraductal Papillary Mucinous Neoplasms. Presented at the American Gastroenterological Meeting, May, 2009. Published *Gastroenterology* 2009.
 42. Hwang C, Kumar S, Lucas AL, Verna EC, Khanna LG, Martinez-Gomez J, Chabot JA, **FRUCHT H**. Clinical Genetic Testing in Prospective Risk Assessment of Pancreatic Cancer Kindreds: The Experience at One Academic Center. Presented at the American Gastroenterological Meeting, May, 2009. Published *Gastroenterology* 2009.
 43. Shankaran V, Luu TH, Nonzee N, McKoy JM, Zivin JG, Ashford AR, Lantigua R, **FRUCHT H**, Scoppettone M, Bennett CL, Gorin SS. Cost-Effectiveness of a Health Care Provider-

- Directed Intervention to Promote Colorectal Cancer Screening. Presented at the American Society of Clinical Oncology Meeting, May, 2009. Published *Proceedings of the American Society of Clinical Oncology* 2009;27:343s.
44. Chang M, Shah J, Gonzalez S, Prowda J, Cheng J, Verna E, Rockey D, **FRUCHT H**. The Utility of Computed Tomographic Colonography in Colorectal Cancer Screening is Limited by Poor Understanding of the Test's Capability. Presented at the American College of Gastroenterology Meeting, October, 2009. Published *American Journal of Gastroenterology* 2009;104(S3)#1473.
 45. Khanna LG, Hwang C, Mitchel EB, Kumar S, Lucas AL, Pursell LJ, Martinez-Gomez J, Chabot JA, **FRUCHT H**. Impact of Family History of Pancreatic and Associated Syndromic Cancers on Disease Survival in Intraductal Papillary Mucinous Neoplasms. Presented at the American Gastroenterological Meeting, May, 2010. Published *Gastroenterology* 2010.
 46. Hwang C, Mitchel EB, Sharaiha RZ, Chung W, **FRUCHT H**. Attitudes Toward Genetic Testing for Pancreatic Cancer Risk Assessment in High-Risk Families. Presented at the American Gastroenterological Meeting, May, 2010. Published *Gastroenterology* 2010.
 47. Kumar S, Hwang C, Pursell LJ, Khanna LG, 2, Lucas AL, Martinez-Gomez J, Chabot JA, **FRUCHT H**. Pathologic Characteristics of Resected Pancreatic Adenocarcinomas That Adversely Affect Survival: An 18-Year Experience At One Academic Center. Presented at the American Gastroenterological Meeting, May, 2010. Published *Gastroenterology* 2010.
 48. Kumar S, Hwang C, Verna EC, Mitchel EB, Stevens PD, **FRUCHT H**. Determining Optimal Surveillance Intervals in Pancreatic Cancer Screening for Asymptomatic High-Risk Individuals: Short-Term Follow-Up Demonstrates No Clinically Significant Findings. Presented at the American Gastroenterological Meeting, May, 2010. Published *Gastroenterology* 2010.
 49. Lucas AL, Hwang C, Mitchel EB, Khanna L, Kumar S, Ludwig T, Shakya R, Chabot JA, Chung WK, **FRUCHT H**. Demonstration of BRCA Germline Mutations In A Series of Resected Pancreatic Adenocarcinomas and Other Lesions. Published *Gastroenterology* 2010.
 50. Lucas AL, Genkinger J, Kumar S, Khanna LG, Martinez-Gomez J, **FRUCHT H**. Pedigrees Obtained by a Genetic Counselor Compared with Self-Reported Health History Questionnaire Demonstrate Strong Agreement in First-Degree Relatives but Moderate to Poor Agreement in Second- and Third-Degree Relatives. Presented at the American Gastroenterological Meeting, May, 2011. Published *Gastroenterology* 2011.
 51. Lucas AL, Mitchel EB, Hwang C, Kumar S, Deng L, Shakya R, Ludwig T, Chabot JA, Chung W, **FRUCHT H**. High Frequency of *BRCA1* and *BRCA2* Germline Mutations In a Series of Resected Pancreatic Adenocarcinoma and Other Preneoplastic Lesions Suggests an Association with *BRCA1* and *BRCA2* Mutations. Presented at the American Gastroenterological Meeting, May, 2011. Published *Gastroenterology* 2011.
 52. Kumar S, Amin S, Engelstadt K, Lucas AL, Khanna LG, Hwang C, Chung W, **FRUCHT H**. High *BRCA 1/2* Mutation Rate With Less Significant Breast Cancer Among Families with Pancreatic Cancer Predisposition: A New Indication for *BRCA 1/2* Testing? Presented at the American Gastroenterological Meeting, May, 2011. Published *Gastroenterology* 2011.
 53. Campos Serrano A, Khanna LG, Amin S, Lucas AL, **FRUCHT H**. Pancreatic Cancer in Minority Patients: The Experience at One Academic Center from 2002-2010. Presented at the American Gastroenterological Meeting, May, 2011. Published *Gastroenterology* 2011.
 54. Amin S, **FRUCHT H**. Evidence for Treatment and Survival Disparities by Age in Pancreatic Adenocarcinoma: A Population Based Analysis. Presented at the American Gastroenterological Meeting, May, 2011. Published *Gastroenterology* 2011.
 55. Amin S, Kumar S, Chabot JA, **FRUCHT H**. Significantly Improved Survival from Pancreatic Adenocarcinoma in a High-Volume Multidisciplinary Pancreas Center. Presented at the American Gastroenterological Meeting, May, 2011. Published *Gastroenterology* 2011.
 56. Khanna LG, Amin S, Kumar S, Lucas AL, Pursell L, Chabot JA, **FRUCHT H**. Timeline of Progression from Adenoma to Invasive Carcinoma in Intraductal Papillary Mucinous

- Neoplasms. Presented at the American Gastroenterological Meeting, May, 2011. Published *Gastroenterology* 2011.
57. Hwang C, Kumar S, Yab TC, Taylor WR, Kisiel JB, Lucas AL, Chabot JA, Ahlquist DA, **FRUCHT H**. Noninvasive Detection of Intraductal Papillary Mucinous Neoplasms (IPMN) and Early Stage Cancer of the Pancreas with Stool DNA Testing. Presented at the American Gastroenterological Meeting, May, 2011. Published *Gastroenterology* 2011.
 58. Lucas AL, Shakya R, Lipsyc M, Mitchel EB, Kumar S, Hwang C, Deng L, DeVoe C, Szabolcs M, Ludwig T, Chabot JA, Chung W, **FRUCHT H**. Demonstration of a High Frequency of *BRCA1* and *BRCA2* Germline Mutations With Loss of Heterozygosity: A Series of Resected Pancreatic Adenocarcinomas and Other Preneoplastic Lesions. Presented at the American Gastroenterological Meeting, May, 2012. Published *Gastroenterology* 2012.
 59. Mitchel EB, Amin S, Lucas AL, Hwang C, Chung W, **FRUCHT H**. Attitudes Toward Genetic Testing and Risk Perception in Pancreatic Cancer Patients and High-Risk Individuals: Understanding the Patient's Perspective. Presented at the American Gastroenterological Meeting, May, 2012. Published *Gastroenterology* 2012.
 60. Khanna LG, Salomao M, Kumar S, Hwang C, Lucas AL, Mitchel EB, Stavropoulos SN, Rotterdam H, **FRUCHT H**. EUS Features of Chronic Pancreatitis Do Not Correlate with Pathologic Findings of Abnormal Parenchyma in High-Risk Pancreas Cancer Patients Undergoing Pancreatic Resection. Presented at the American Gastroenterological Meeting, May, 2012. Published *Gastroenterology* 2012.
 61. Kumar S, Amin S, Hwang C, Verna EC, Chua J, Mitchel EB, Lucas AL, Khanna LG, **FRUCHT H**. Interval Follow-Up of High-Risk Pancreatic Cancer Screening Patients Demonstrates No Significant Lesions Within One Year. Presented at the American Gastroenterological Meeting, May, 2012. Published *Gastroenterology* 2012.
 62. Amin S, **FRUCHT H**. Patient Refusal of Surgery for Pancreatic Adenocarcinoma May Contribute to Poor Survival: A Population Based Study. Presented at the American Gastroenterological Meeting, May, 2012. Published *Gastroenterology* 2012.
 63. Amin S, Kim MK, **FRUCHT H**. Duodenal Carcinoid Tumors Are Associated With Increased Survival and Earlier Detection When Compared with Jejunal or Ileal Carcinoids: A Population Based Study. Presented at the American Gastroenterological Meeting, May, 2012. Published *Gastroenterology* 2012.
 64. Frado LE, Hwang C, Kumar S, Khanna L, Chung W, **FRUCHT H**, Lucas AL. *BRCA1* and *BRCA2* Germline Mutations are Frequently Found in a High-Risk Pancreatic Cancer Screening Population. Presented at the American College of Gastroenterology Meeting, October, 2012.
 65. Hassid B, Salomao M, Weng C, Liu F, Khanna L, Kumar S, Hwang C, Chabot JA, **FRUCHT H**, Lucas AL. Absence of Pancreatic Intraepithelial Neoplasia (PanIN) Predicts Poor Survival Following Resection of Pancreatic Cancer. Presented at the American College of Gastroenterology Meeting, October, 2012.
 66. Amin S, **FRUCHT H**, Lucas AL. Improved Survival Is Demonstrated Among Asian-Americans with Pancreatic Adenocarcinoma But May Not Be Explained by Increased Treatment. Presented at the American Gastroenterological Meeting, May, 2013. Published *Gastroenterology* 2013.
 67. Amin S, Kim MK, Lucas AL, **FRUCHT H**. Decreased Survival and Surgical Intervention with Aging for Pancreatic Neuroendocrine Tumors: A Population Based Analysis. Presented at the American Gastroenterological Meeting, May, 2014. Published *Gastroenterology* 2014.
 68. Amin S, Kim MK, Lucas AL, **FRUCHT H**. Increased Survival Over Time of Individuals With Gastrinomas: A Population Based Analysis. Presented at the American Gastroenterological Meeting, May, 2014. Published *Gastroenterology* 2014.